|Articles|April 10, 2009 (Updated: November 15, 2020)

WOTY- Podcast-Howson

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Novo Nordisk Invests $506 Million in Ireland Manufacturing Facility Expansion

ByNicholas Jacobus

March 3rd 2026

Patent Term Extension: Challenges with Defining and Claiming Approved Biologics

ByJessica von Reyn

March 3rd 2026

Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya

ByNicholas Jacobus

March 2nd 2026

FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria

ByNicholas Jacobus

March 2nd 2026

FDA Approves Sogroya as First and Only Weekly Long-Acting Growth Hormone for Pediatrics

ByNicholas Jacobus

March 2nd 2026

WOTY- Podcast-Howson

Newsletter

Related Content

Novo Nordisk Invests $506 Million in Ireland Manufacturing Facility Expansion

Patent Term Extension: Challenges with Defining and Claiming Approved Biologics

Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya

FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria

FDA Approves Sogroya as First and Only Weekly Long-Acting Growth Hormone for Pediatrics

Trending on PharmExec

Real-World Data Brings New Insights to Natural History of Disease Studies

Pharmaceutical Executive Daily: FDA Approves Palynziq and Sogroya

FDA Approves Hernexeos Under National Priority Voucher Program

FDA Approves New Indication of Palynziq for Patients 12 Years and Older with Phenylketonuria

Patent Term Extension: Challenges with Defining and Claiming Approved Biologics